BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Bristol-Myers Squibb Company 

345 Park Avenue

New York  New York  10154  U.S.A.
Phone: 212-546-4000 Fax: 212-546-4020


SEARCH JOBS




 Key Statistics


Email:
Ownership: Public

Web Site: Bristol-Myers Squibb
Employees:
Symbol: BMY
 





Collaborations

Gilead 

PanVera LLC 

Pharmagene Laboratories Limited 

Johnson & Johnson 

Amersham Biosciences 

Lexicon Genetics Incorporated 

Athersys, Inc.  Athersys will provide Bristol-Myers Squibb with cell lines expressing validated drug targets produced using the RAGE-Validated Target technology. BMS plans to use its combinatorial chemistry capabilities to develop small molecule drug candidates against the validated targets.

Merck & Co.  Diabetes

Affinimark Technologies Inc. 

GlaxoSmithKline (North Carolina) 

Medarex, Inc. 

Gilead (Durham, NC) 

Phyton Biotech, Inc.  - Cancer

Gilead (Seattle, WA) 





 Company News
Bristol-Myers Squibb (BMY) To Announce Results For First Quarter 2015 On April 28 3/27/2015 10:02:53 AM
European Regulators Postpone Bristol-Myers Squibb (BMY)’s Opdivo Decision Until April or Later, As Markets Wait Anxiously 3/27/2015 8:58:24 AM
Bristol-Myers Squibb (BMY) Acquires Exclusive License From Novo Nordisk A/S (NVO) For A Discovery Research Program Focused On Autoimmune Diseases 3/24/2015 10:37:29 AM
Zai Lab In-licenses Potential Liver Cancer Drug From Bristol-Myers Squibb (BMY) 3/23/2015 10:14:11 AM
Bristol-Myers Squibb (BMY) Announces Acceptance Of New Drug Application For Investigational Daclatasvir For FDA Review For The Treatment Of Hepatitis C Genotype 3 3/13/2015 8:15:46 AM
Bristol-Myers Squibb (BMY) Grabs Record Fast Approval for Opdivo 3/5/2015 6:34:48 AM
Bristol-Myers Squibb (BMY) Bets $975 Million on Bavarian Nordic (BAVA.CO)'s Prostate Cancer Vaccine 3/4/2015 5:34:00 AM
Bristol-Myers Squibb (BMY) Announces Dividend 3/3/2015 8:55:54 AM
Bristol-Myers Squibb (BMY) Release: U.S. FDA Accepts Biologics Licensing Application For Opdivo (Nivolumab) For The Treatment Of Advancedsquamous Non-Small Cell Lung Cancer 3/2/2015 11:46:20 AM
Bristol-Myers Squibb (BMY) Release: ALLY Trial Demonstrates 97% Hepatitis C Cure Rates Among Patients Coinfected With HIV After Ribavirin-Free Investigational 12-Week Regimen Of Daclatasvir And Sofosbuvir 2/27/2015 10:54:46 AM
12345678910...